Carmel-Neiderman Narin-Nard, Tanne David, Goren Idan, Rotman-Pikielny Pnina, Levy Yair
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Medicine E, Meir Medical Center, Kfar Saba, Israel.
Immunol Res. 2017 Apr;65(2):470-476. doi: 10.1007/s12026-017-8897-z.
Classical antiphospholipid antibodies (aPLa) are found in 6-25% of blood samples from stroke patients. The frequency of novel aPLa antibodies in blood samples of CVA patients is not known. Enzyme-linked immunosorbent assays (ELISA) were performed on blood samples from 209 CVA patients (170 samples were obtained during the acute phase and 39 samples were from patients with complete carotid stenosis) and compared to 54 healthy controls. Subjects were tested for the presence of the classical aPL antibodies anticardiolipin (aCL) and anti-beta2-glycoprotein (aβ2gI), in addition to antiphosphatidylethanolamine (aPE), anti-phosphatidylserine (aPS), and Annexin V. All antibodies were tested for both IgM and IgG subclasses. Numeric analysis of the antibody titer levels (μ/ml) revealed a significantly higher subclinical titer by two standard deviations of many aPL autoantibodies among CVA patients (Pv < 0.05). However, according to the kit manufacturer's cutoff value, no positive antibodies were found except a trend toward higher percentage of positive aPS IgG titer in the CVA group compared to controls (6.2 vs. %0; P = 0.077). According to the manufacturer's cutoff, significantly higher levels of positive antibodies were not found among stroke patients. However, the absolute ELISA values of stroke patients were significantly higher. These results suggest that lower cutoff values than those used for APS diagnosis should be used for risk stratification of CVA among healthy individuals.
在中风患者的血液样本中,6%-25%可检测到经典抗磷脂抗体(aPLa)。目前尚不清楚脑血管意外(CVA)患者血液样本中新型aPLa抗体的出现频率。对209例CVA患者的血液样本(170份样本采集于急性期,39份样本来自完全性颈动脉狭窄患者)进行了酶联免疫吸附测定(ELISA),并与54名健康对照者进行比较。除了检测抗磷脂酰乙醇胺(aPE)、抗磷脂酰丝氨酸(aPS)和膜联蛋白V外,还对受试者检测了经典抗磷脂抗体抗心磷脂(aCL)和抗β2糖蛋白(aβ2gI)。所有抗体均检测了IgM和IgG亚类。对抗体滴度水平(μ/ml)进行数值分析发现,CVA患者中许多抗磷脂自身抗体的亚临床滴度显著高于健康对照者两个标准差(Pv<0.05)。然而,根据试剂盒制造商的临界值,除了CVA组中aPS IgG滴度阳性百分比有高于对照组的趋势外(6.2%对0;P=0.077),未发现阳性抗体。根据制造商的临界值,中风患者中未发现阳性抗体水平显著升高。然而,中风患者的ELISA绝对值显著更高。这些结果表明,对于健康个体中CVA的风险分层,应采用低于用于抗磷脂综合征(APS)诊断的临界值。